SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEssentra Regulatory News (ESNT)

Share Price Information for Essentra (ESNT)

Share Price is delayed by 15 minutes
Get Live Data
85.20    1.20 (1.43%)
Bid:
85.20
Ask:
85.90
Spread: 0.70 (0.822%)
Market Cap: £238.73m
ESNT Live PriceLast checked at - London Stock Exchange

Intraday Essentra Share Chart

Q3 2025 Trading Update

30 Oct 2025 07:00

RNS Number : 4035F
Essentra plc
30 October 2025
 

ESSENTRA PLC

("Essentra", the "Group", or the "Company")

Q3 TRADING UPDATE

Sales growth amid mixed market conditions

Essentra plc, a leading global provider and manufacturer of essential components and solutions, today issues a trading update for the third quarter, covering the thirteen weeks ended 27 September 2025 ("Q3" or the "period").

Trading performance

Revenue in Q3 increased by 5.9% at constant currency on a like-for-like¹, working day-adjusted basis, reflecting year-on-year recovery as certain end-market conditions slowly improve and comparatives to the prior year ease. The improved performance was delivered whilst continuing to navigate mixed market conditions, as indicated by widely reported manufacturing PMI trends. Group new order intake increased by 5.6% in Q3 compared to the prior year, with September returning to Q2 2025 levels following seasonally softer trading in July and August.

Consistent with H1 2025, EMEA revenue performance during the period was mixed. The region returned to year-on-year growth against soft prior-year comparatives, further supported by a strong relative performance in Turkey, which continues to benefit from faster-growing end-markets, the implementation of pricing initiatives and local currency devaluation. EMEA ex-Turkey experienced subdued demand across the quarter, particularly in higher margin UK and Western European geographies. The Americas maintained its year-on-year growth momentum, delivering revenue in the period in line with Q2 levels. Performance was supported by pricing initiatives and increased stability within distributor end-channels. The APAC region continues to be driven by market dynamics in China, supported by a number of business wins in faster-growing end-markets.

Management remains focused on delivering operational efficiencies in the near term, while selectively reinvesting for growth in line with regional demand. In EMEA, investment in service continues alongside ERP deployment, while pricing initiatives are progressing, particularly in the Americas. The previously announced footprint rationalisation measures, as outlined at the HY25 results, remain on track.

The Group's financial position remains robust. FY25 leverage is expected to remain within the medium-term target range of 0.5x to 1.5x, supported by strong operating and free cash flow conversion. Essentra's acquisition pipeline remains strong, with management actively engaged in reviewing a number of bolt-on opportunities.

Outlook

As expected, Essentra delivered year-on-year revenue growth and an improving order intake through the third quarter which has continued into October. While the Group remains cautious about the timing of any material recovery in market conditions, actions taken to streamline the cost base and optimise operations will protect profitability and allow Essentra to benefit from significant operational gearing as market conditions improve.

Given the strength of Essentra's operations in Turkey, which generate lower margins compared to the rest of EMEA, the Group's overall gross margin was slightly weaker than expected in the period and this effect is likely to continue into the final quarter of the year. As such, management now anticipates that the full year adjusted operating margin will remain consistent with the first half of the year.

The Board remains confident in the Group's ability to deliver its medium-term strategic and financial targets underpinned by continued progress on operational initiatives and a strong pipeline of value-enhancing organic and inorganic growth opportunities.

Enquiries

Essentra plc

Rowan Baker, Chief Financial Officer

Claire Goodman, Head of Investor Relations

Tel: +44 (0)1908 359100

FTI Consulting

Richard Mountain

Ariadna Peretz

FTI_essentra@fticonsulting.com

Tel: +44 (0)20 3727 1340

 

Notes

1. The term "like-for-like" describes the performance of the business on a comparable basis, adjusting for the impact of acquisitions, disposals and foreign exchange

 

 

About Essentra plc

Essentra plc is a leading global provider of essential components and solutions, focusing on the manufacture and distribution of plastic injection moulded, vinyl dip moulded and metal items.

Headquartered in the United Kingdom, Essentra's global network extends to 28 countries worldwide and includes c.3,000 employees, 14 manufacturing facilities, 26 distribution centres and 37 sales & service centres serving c.64,000 customers with a rapid supply of low cost but essential products for a variety of applications in industries such as equipment manufacturing, automotive, fabrication, electronics, medical and renewable energy. For further information, please visit www.essentraplc.com

LEI: 5493007MOZNA03BVNE96

Cautionary forward-looking statement

These results contain forward-looking statements based on current expectations and assumptions. Various known and unknown risks, uncertainties and other factors may cause actual results to differ from future results or developments expressed or implied from the forward-looking statements. Each forward-looking statement speaks only as of the date of this document. The Company accepts no obligation to revise or update these forward-looking statements publicly or adjust them to future events or developments, whether as a result of new information, future events or otherwise, except to the extent legally required.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFSTIELAFIE
Date   Source Headline
10th Jun 20269:47 amRNSHolding(s) in Company
1st Jun 20267:00 amRNSTotal Voting Rights
29th May 20262:32 pmRNSTransaction in Own Shares
21st May 202610:55 amRNSResult of AGM
20th May 20267:00 amRNSAcquisition of Boteco Srl
20th May 20267:00 amRNS2026 AGM Trading Update
14th May 20265:15 pmRNSDirector/PDMR Shareholding
12th May 20267:03 amRNSTransaction in Own Shares
1st May 202612:17 pmRNSTotal Voting Rights
29th Apr 20268:12 amRNSTransaction in Own Shares
28th Apr 20263:25 pmRNSDirector/PDMR Shareholding
24th Apr 20263:30 pmRNSDirector/PDMR Shareholding
22nd Apr 20268:15 amRNSTransaction in Own Shares
21st Apr 20264:09 pmRNSDirector/PDMR Shareholding
17th Apr 20267:52 amRNSHolding(s) in Company
15th Apr 202610:06 amRNSDirector/PDMR Shareholding
15th Apr 20268:24 amRNSTransaction in Own Shares
15th Apr 20268:18 amRNSHolding(s) in Company
9th Apr 20268:24 amRNSDirector/PDMR Shareholding
7th Apr 20267:00 amRNSDirector/PDMR Shareholding
7th Apr 20267:00 amRNSHolding(s) in Company
1st Apr 20264:45 pmRNSDirector/PDMR Shareholding
1st Apr 20263:21 pmRNSDirector/PDMR Shareholding
1st Apr 20263:15 pmRNSTransaction in Own Shares
1st Apr 20263:08 pmRNSTotal Voting Rights
30th Mar 20262:00 pmRNSAnnual Financial Report
24th Mar 202610:05 amRNSTransaction in Own Shares
24th Mar 20268:17 amRNSHolding(s) in Company
19th Mar 20268:43 amRNSDirector/PDMR Shareholding
17th Mar 20261:41 pmRNSDirector/PDMR Shareholding
17th Mar 202610:30 amRNSDirectorate change
17th Mar 202610:28 amRNSDirector/PDMR Shareholding
17th Mar 20267:00 amRNSResults for the Full Year Ended 31 December 2025
17th Mar 20267:00 amRNSResults for the Full Year Ended 31 December 2025
16th Mar 20269:40 amRNSTransaction in Own Shares
16th Mar 20269:40 amRNSTransaction in Own Shares
13th Mar 202612:00 pmRNSCompany Secretary Change
9th Mar 20269:00 amRNSNotice of Full Year 2025 Results
9th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTotal Voting Rights
26th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares
23rd Feb 20267:00 amRNSTransaction in Own Shares
20th Feb 20267:58 amRNSHolding(s) in Company
19th Feb 20267:00 amRNSTransaction in Own Shares
18th Feb 202612:20 pmRNSHolding(s) in Company
17th Feb 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.